Business · 08/06/2012Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on KALBITOR Patent Extension Review Period
Summary
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on May 2, 2012, due to an error in the patent number for KALBITOR, a medication subject to patent extension review.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →